Pe 22-28 Certificate Of Analysis

Understanding the PE-22-28 Certificate of Analysis (COA)

A Certificate of Analysis for the PE-22-28 research peptide serves as the primary instrument of quality assurance for laboratory investigators. Because synthetic peptides can vary in purity depending on solid-phase peptide synthesis (SPPS) efficiency, cleavage conditions, and purification protocols, a lot-specific COA provides verifiable proof that the material matches its theoretical specifications. Every certificate issued for PX1 Research compounds represents rigorous, batch-specific testing conducted by independent, third-party laboratories.

When evaluating a PE-22-28 COA, researchers must verify key standard parameters including physical appearance, solubility, counterion content, theoretical molecular weight versus observed mass, chemical purity percentage, and residual endotoxin concentrations. Without these empirical metrics, unexpected chromatographic artifacts, synthesis truncated sequences, or residual reagents can confound electrophysiological and cellular assays.

At PX1 Research, every batch of PE-22-28 undergo comprehensive testing in ISO 17025 accredited facilities. To learn more about our rigorous quality standards across our entire catalog, investigators can explore our overview of peptide purity testing methodologies.

Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) Purity Benchmarks

The primary quantitative metric on a PE-22-28 Certificate of Analysis is chemical purity, determined via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). RP-HPLC separates the target peptide from synthesis-related impurities—such as deletion sequences, incomplete cleavage products, and oxidized species—based on hydrophobic interactions with a stationary phase column.

The resulting chromatogram displays peak integration, where the relative area under the curve (AUC) of the primary peak corresponds to the overall peptide purity percentage. For reliable laboratory research use, PE-22-28 must meet or exceed a 98.0% purity threshold. The COA must include the full chromatogram, specifying column type, mobile phase gradient (typically water/acetonitrile containing 0.1% trifluoroacetic acid), flow rate, UV detection wavelength (usually 214 nm or 220 nm), and retention time.

High purity ensures that observed biological activity in cell cultures or tissue preparations is attributable strictly to the PE-22-28 sequence rather than contaminating peptide fragments that might interact non-specifically with cellular targets.

Mass Spectrometry (MS) and Sequence Identity Verification

While RP-HPLC establishes chemical purity, it cannot independently confirm the precise molecular structure or sequence identity of PE-22-28. Mass Spectrometry (MS)—typically utilizing Electrospray Ionization (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF)—is employed to determine the exact molecular mass of the compound.

PE-22-28 is a synthetic 7-amino acid derivative (Gln-Pro-Gly-Thr-Pro-Pro-Gly or derivative structure designed as a spadin analog). The COA explicitly compares the theoretical molecular weight (calculated from the amino acid composition) against the experimentally observed mass-to-charge (m/z) ratio. Matching these values confirms that the correct peptide sequence was synthesized without amino acid substitutions, deletions, or unexpected side-chain modifications.

A complete COA displays the primary mass spectrum with clearly labeled monoisotopic or average mass peaks. Combining RP-HPLC purity integration with ESI-MS mass verification provides complete confidence in the identity and physical integrity of the research compound.

Bacterial Endotoxin Limits and Bioburden Control

For in vitro cell culture, brain slice preparations, and animal tissue studies, bacterial endotoxin contamination poses a critical threat to experimental validity. Endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—can trigger robust inflammatory signaling pathways, altering ion channel kinetics, gene expression, and cellular viability independently of the test peptide.

PE-22-28 COAs from PX1 Research feature quantitative endotoxin testing performed via the Limulus Amebocyte Lysate (LAL) assay or recombinant Factor C (rFC) assay. The results are expressed in Endotoxin Units per milligram (EU/mg). Standard specifications require endotoxin levels to remain strictly under <0.01 EU/mg, minimizing the risk of non-specific inflammatory artifacts during neurobiological investigations.

Researchers interested in the impact of bioburden on cell line stability can consult our detailed technical brief on endotoxin limits in cell culture assays.

Chemical Identity, Sequence Structure, and TREK-1 Target Mechanism

PE-22-28 was engineered as a shortened, synthetic analog of spadin, a naturally occurring 22-amino acid peptide cleaved from the propeptide of sortilin. Preclinical studies suggest that spadin and its shorter synthetic derivatives function as selective blockers of the TREK-1 (KCNK2) two-pore domain potassium channel.

TREK-1 channels play a fundamental role in maintaining resting membrane potential and modulating neuronal excitability throughout the central nervous system. In vitro electrophysiological recordings indicate that PE-22-28 binds to the extracellular region of the TREK-1 channel, inhibiting potassium efflux and subsequently depolarizing the neuronal membrane.

Because of its reduced molecular size compared to native spadin, PE-22-28 demonstrates enhanced metabolic stability and receptor binding kinetics in rodent tissue models. In-depth mechanistic papers and pathway analyses can be reviewed within the broader PX1 Research knowledge base.

Preclinical Literature & In Vitro Findings on PE-22-28

In vitro data indicate that PE-22-28 exhibits nanomolar affinity for the TREK-1 channel, displaying high selectivity over related two-pore domain potassium channels such as TREK-2 and TRAAK. Patch-clamp electrophysiology studies on transfected HEK293 cells and isolated hippocampal neurons demonstrate rapid and reversible channel inhibition following application of PE-22-28.

Animal study models evaluating neuroplasticity markers report that central or systemic administration of PE-22-28 leads to increased synaptogenesis, elevated neurotrophic factor expression (such as BDNF), and enhanced hippocampal neurogenesis in adult rodent models. These preclinical observations suggest that TREK-1 inhibition plays a key regulatory role in neuronal survival and synaptic remodeling pathways.

Furthermore, behavioral rodent assays (such as the forced swim test and novel object recognition tasks) have been utilized in preclinical literature to assess the functional downstream outcomes of TREK-1 blockade, establishing PE-22-28 as a valuable tool peptide for neuropharmacological research.

Comparative Analysis: PE-22-28, Spadin, and Neuroactive Research Compounds

To understand the specific research utility of PE-22-28, it is helpful to compare it against full-length spadin and other prominent neuroactive research peptides studied in preclinical cognitive and neuroplasticity models.

Full-length spadin (a 22-mer peptide) shares the same TREK-1 inhibition mechanism as PE-22-28, but exhibits a shorter enzymatic half-life in rodent plasma assays due to rapid cleavage by endogenous endopeptidases. In contrast, PE-22-28 was specifically truncated and stabilized to optimize bioactivity while retaining target selectivity. Detailed discussions regarding channel kinetics can be found in our guide to TREK-1 channel dynamics.

When evaluated alongside other neuro-focused research compounds such as Semax and Selank, distinct operational mechanisms emerge. While Semax operates primarily through BDNF/TrkB upregulation and melanocortin receptor modulation, and Selank influences GABAergic signaling and enkephalin degradation, PE-22-28 acts directly as an ion channel antagonist. Reviewing all available all research compounds allows researchers to select the appropriate mechanism for their specific experimental design.

Reconstitution, Handling, and Storage Protocols for Laboratory Use

To preserve the chemical integrity validated in the PE-22-28 Certificate of Analysis, strict reconstitution and storage protocols must be maintained within the laboratory. Lyophilized PE-22-28 should be stored at -20°C or -80°C in a desiccated environment upon receipt to prevent hydrolytic degradation.

When reconstituting PE-22-28 for in vitro or ex vivo assays, researchers should use sterile, bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4). Gentle swirling is recommended; vortexing or vigorous agitation can induce mechanical shear stress and peptide aggregation. If necessary, initial solubilization can be aided by a brief application of 0.1% acetic acid prior to diluting into neutral buffers.

Reconstituted solutions should be divided into single-use working aliquots and stored at -80°C to eliminate repeated freeze-thaw cycles, which accelerate physical degradation. Detailed parameters regarding concentration calculations and solvent compatibility are detailed in our comprehensive reconstitution and storage protocols.

Sourcing Standards: US Manufacturing and ISO 17025 Compliance

The scientific validity of any preclinical study depends directly on the quality and consistency of the starting reagents. PX1 Research synthesizes all peptides in state-of-the-art, GMP-compliant facilities located in the United States, adhering strictly to automated solid-phase synthesis protocols.

Every production lot undergoes independent verification in an ISO 17025 accredited laboratory to guarantee that published COA metrics represent unbiased, reproducible analytical data. We ensure complete lot traceability from raw amino acid coupling to final lyophilization and packaging. Principal investigators and institutional buyers seeking bulk procurement or custom analytical specifications can submit inquiries via our wholesale lab procurement portal.